NASDAQ:DMRA Damora Therapeutics, Inc. Common Stock Q4 2024 Earnings Results & Report $21.08 +0.52 (+2.53%) As of 10/9/2026 04:00 PM Eastern Damora Therapeutics, Inc. Common Stock missed analyst earnings expectations in its Q4 2024 results, released March 19, 2025. The company reported EPS of -$5.22 versus the -$3.12 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2024Report DateMarch 19, 2025TimeBefore Market OpensConference Call DateMarch 18, 2025Conference Call7:00 PM ET Damora Therapeutics, Inc. Common Stock EPS ResultsActual EPS-$5.22Consensus EPS -$3.12Beat/MissMissed by -$2.10One Year Ago EPSN/AEPS Beat Rate6 of last 8 quartersDamora Therapeutics, Inc. Common Stock Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesAnnual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsAnnual report(10-K) Damora Therapeutics, Inc. Common Stock Q4 2024 Earnings FAQ Did Damora Therapeutics, Inc. Common Stock beat earnings estimates for Q4 2024? Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) reported earnings of -$5.22 per share for Q4 2024, missing the consensus estimate of -$3.12. The report was announced on Wednesday, March 19, 2025. Damora Therapeutics, Inc. Common Stock Earnings HeadlinesDamora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Stock Rating Lowered by Wall Street ZenOctober 3, 2026 | americanbankingnews.comDamora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 2, 2026 | globenewswire.comTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered. Buried inside is what some call the legal groundwork for the biggest change to American money in over a century, with a key Treasury vote potentially as soon as January 18. Ian King, Chief Strategist at Strategic Fortunes, breaks down what the order could mean for the dollar and the financial system.October 10 at 1:00 AM | Banyan Hill Publishing (Ad)Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Earns Outperform Rating from WedbushOctober 1, 2026 | americanbankingnews.comDamora CEO buys 12,500 shares in open marketSeptember 30, 2026 | americanbankingnews.comDamora Therapeutics Insider Bought Shares Worth $252,875, According to a Recent SEC FilingSeptember 29, 2026 | marketscreener.comMSee More Damora Therapeutics, Inc. Common Stock Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Damora Therapeutics, Inc. Common Stock? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Damora Therapeutics, Inc. Common Stock and other key companies, straight to your email. Email Address About Damora Therapeutics, Inc. Common StockGalecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.View Damora Therapeutics, Inc. Common Stock ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep ValueMicrosoft Is Almost Back to $555—Now the Hard Part Begins Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
